Case reports demonstrate effective local control of primary pulmonary non-Hodgkin lymphoma through targeted radiotherapy, suggesting its key role in treatment.
Primary pulmonary non-Hodgkin lymphoma (PPL) is a rare malignancy most commonly presented as indolent marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or bronchus-associated lymphoid tissue (BALT). Aggressive subtypes of PPL, such as diffuse large B-cell lymphoma (DLBCL), occur less frequently. Diagnosis and workup require tissue biopsy, immunophenotyping, and cross-sectional imaging, often supplemented by positron emission tomography (PET)/computed tomography (CT) for staging and treatment planning. Radiation therapy or radiotherapy (RT) is a cornerstone in managing localized, indolent PPL, offering durable local control with minimal toxicity. Modern involved-site RT (ISRT) techniques deliver radiation in conventional fractionation schedules, precisely targeting pulmonary lesions while sparing surrounding lung and mediastinal structures. RT can be used alone for early-stage disease or following systemic therapy for residual or refractory lesions. The cases in this report highlight the importance of histology-driven, individualized treatment planning and the pivotal role of RT in achieving optimal outcomes in this rare malignancy.
No takes yet. Share an insight, caveat, or question.
Fahmy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: